Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.

NCT05209243 is registered in ClinicalTrials.gov with Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic as lead sponsor.

NCT NCT05209243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05209243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.
Lead sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase
Not applicable
Overall status
Recruiting
Start date
January 26, 2023
Completion date
January 31, 2027
Enrollment
266 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, stereotactic body radiation therapy